Hyperbolic heterogeneous graph learning for adverse drug reaction prediction, candidate prioritization, and pathway-based interpretation in pharmacovigilance.
Lv Ru R, Xu Xiaoyu X, Ji Yulin Y, Wei Jianxiang J et al.
Adverse drug reaction (ADR) prediction remains challenging because spontaneous reporting data leave many exposure unit-ADR associations unobserved and provide limited support for candidate prioritization and mechanistic interpretation. We developed MEG-HHGN, a mechanistic evidence-guided hyperbolic heterogeneous graph neural network. It represents exposure units as combinations of standardized drug names and routes of administration and integrates spontaneous reports with compounds, drug targets, ADR-related targets, and protein-protein interactions. Using 73,530 spontaneous reports collected in Jiangsu Province from 2010 to 2023, we evaluated MEG-HHGN against eight baseline methods through five-fold cross-validation. MEG-HHGN achieved AUC/AP/MCC values of 0.9550/0.9537/0.7917 in known-exposure-unit completion and 0.9090/0.9064/0.6587 in side-information-supported exposure-unit cold-start evaluation. Global scoring of unobserved exposure unit-ADR pairs produced a ranked candidate pool for pharmacovigilance review. Representative cases involving intravenous vinorelbine tartrate-myelosuppression and oral aspirin-proteinuria illustrated PPI-bridged and shared-target pathways, respectively. MEG-HHGN integrates route-aware prediction, candidate prioritization, and pathway-based interpretation in a unified framework to support signal triage, mechanistic hypothesis generation, and evidence review in post-marketing pharmacovigilance.